Fosnetupitant

DB14019ApprovedInvestigationalSmall moleculeSubstance P/Neurokinin-1 Receptor Antagonist

Fosnetupitant is a medication used in combination with others to prevent chemotherapy associated nausea and vomiting. In April 2018, the U.S.

Chemical structure of Fosnetupitant
Mechanism
Curator reviewed · 2 references
Primary indication
Indicated in combination palonosetron (as the drug Akynzeo) and dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited...Curator reviewed · 4 structured indications
Formula / weight
C31H35F6N4O5P · 688.608 g/mol (avg)
First approval
United States, 2018
Code names
07-PNET
Brand names
  • Akynzeo

Resolves to

Clinical / RWD
Structure
InChIKeyHZIYEEMJNBKMJH-UHFFFAOYSA-NSMILESCN(C(=O)C(C)(C)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)C1=CN=C(C=C1C1=CC=CC=C1C)N1CC[N+](C)(COP(O)([O-])=O)CC1

What you can answer from here — as of April 08, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
824Drug interactionsStructured to mechanism, not free text
Sign in
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
4Marketed productsAcross 2 countries and 2 labellers
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Fosnetupitant, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account